Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE

被引：0
|
作者：
Marin, G. [1 ]
Vanderlinden, B. [1 ]
Wimana, Z. [1 ]
Guiot, T. [1 ]
Karfis, I. [1 ]
Flamen, P. [1 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP386
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [31] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [32] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [33] Assessing neuroendocrine tumour response to peptide receptor radionuclide therapy with 177Lu-DOTATATE using voxel-based dosimetry
    Ram, L.
    Bissell, S.
    Hughes, S.
    Ross, E.
    Geh, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S395 - S395
  • [34] Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in 177Lu-DOTATATE peptide receptor radionuclide therapy
    Brolin, Gustav
    Gustafsson, Johan
    Ljungberg, Michael
    Gleisner, Katarina Sjogreen
    PHYSICS IN MEDICINE AND BIOLOGY, 2015, 60 (15): : 6131 - 6149
  • [35] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [36] Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes-90Y/177Lu-DOTATATE in patients with disseminated neuroendocrine tumors
    Kunikowska, J.
    Krolicki, L.
    Pawlak, D.
    Mikolajaczak, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S425 - S426
  • [37] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
  • [38] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [39] Impaired Kidney Function Is Associated with Higher Absorbed Dose to Organs-at-Risk in 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)
    Marin, G.
    Karfis, I
    Levillain, H.
    Reynaert, N.
    Vandenberghe, S.
    Vanderlinden, B.
    Flamen, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 221 - 221
  • [40] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
12345